Research looks at saxagliptin's safety, efficacy in diabetes

09/3/2013 | HealthDay News

Type 2 diabetes patients who took saxagliptin did not have a higher risk of heart attack, stroke or cardiovascular death than those who took a placebo pill, a study in the New England Journal of Medicine indicated. Researchers also found patients in the saxagliptin arm attained better glucose control and reduced insulin therapy requirements. However, researchers noted an increased rate of hospitalization for heart failure among saxagliptin-treated patients, which merits further evaluation.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park